Nuvalent Outlines Pipeline and Business Progress, Reiterates Key Anticipated Milestones, and Reports Fourth Quarter and Full Year 2024 Financial Results [Yahoo! Finance]
Nuvalent, Inc. - Class A (NUVL)
NASDAQ:AMEX Investor Relations:
nuvelinc.com/company/investor_relations.html
Company Research
Source: Yahoo! Finance
First NDA submission planned for mid-year 2025 towards potential first approval in 2026 for zidesamtinib in TKI pre-treated ROS1-positive NSCLC population Development strategies in place for TKI-naïve populations, including planned initiation of ALKAZAR Phase 3 randomized, controlled trial of neladalkib for front-line ALK-positive NSCLC in first half of 2025 Implemented global Expanded Access Programs for zidesamtinib and neladalkib, in line with goal of prioritizing patient access CAMBRIDGE, Mass. Feb. 27, 2025 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today outlined pipeline and business progress, reiterated key anticipated milestones, and reported fourth quarter and full year 2024 financial results. Nuvalent, Inc. (PRNewsfoto/Nuvalent, Inc.) "The efficient execution by the Nuvalent team to date reflects a shared sense of urgency
Show less
Read more
Impact Snapshot
Event Time:
NUVL
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NUVL alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NUVL alerts
High impacting Nuvalent, Inc. - Class A news events
Weekly update
A roundup of the hottest topics
NUVL
News
- Nuvalent (NASDAQ:NUVL) had its price target lowered by analysts at JPMorgan Chase & Co. from $147.00 to $145.00. They now have an "overweight" rating on the stock.MarketBeat
- Nuvalent (NASDAQ:NUVL) had its "buy" rating reaffirmed by analysts at UBS Group AG.MarketBeat
- Royalty Pharma Acquires Royalty Interest in Nuvalent's Neladalkib and Zidesamtinib for Up to $315 Million [Yahoo! Finance]Yahoo! Finance
- Nuvalent Appoints Ron Squarer to Board of DirectorsPR Newswire
- Nuvalent, Inc. (NUVL) is a Buy On lung Cancer Treatment Prospects [Yahoo! Finance]Yahoo! Finance
NUVL
Earnings
- 5/8/25 - Miss
NUVL
Sec Filings
- 12/16/25 - Form 8-K
- 12/11/25 - Form 4
- 12/11/25 - Form 3
- NUVL's page on the SEC website